A meta-analysis of six RCTs and two observational studies totaling nearly 29,000 patients found semaglutide was associated with a 26% reduction in heart failure-related clinical events compared to placebo or control groups.
26% heart failure risk reductionSemaglutide was associated with OR 0.74 (95% CI: 0.58-0.94) for heart failure events across nearly 29,000 patients from 8 studies — a clinically meaningful reduction confirmed by sensitivity analysis.
What the researchers found
Across 6 RCTs (28,762 patients) and 2 observational studies:
- Semaglutide group: 14,608 subjects
- Control/placebo group: 14,716 subjects
- Heart failure risk: OR 0.74 (95% CI: 0.58-0.94) — a 26% reduction
- Heterogeneity: I² = 45% (moderate)
- No evidence of publication bias
- Sensitivity analysis confirmed robust results
Why it matters
Heart failure affects 64 million people worldwide and has a 5-year mortality rate of approximately 50%. Current treatments can slow progression but rarely reverse the condition. A 26% reduction in heart failure events from a drug already widely prescribed for diabetes and obesity could have enormous public health impact. If confirmed in dedicated heart failure trials, semaglutide could become a new standard of care — particularly valuable because it simultaneously addresses weight, diabetes, and cardiovascular risk.
How the study worked
This PRISMA-compliant meta-analysis searched for randomized clinical trials and observational cohort studies assessing semaglutide's effects on heart failure-related outcomes with ≥6 months follow-up. Six RCTs and two observational studies met inclusion criteria. Data were pooled using a random-effects model (appropriate given the heterogeneous study designs and populations). Publication bias was assessed analytically, and sensitivity analyses tested the robustness of the overall finding.
What this study cannot tell us
The meta-analysis includes studies with different patient populations (diabetes trials, obesity trials), different semaglutide doses, and different heart failure definitions, contributing to moderate heterogeneity (I²=45%). Most included trials were not primarily designed to study heart failure outcomes, meaning heart failure events were secondary or exploratory endpoints with potentially inconsistent ascertainment. The inclusion of observational studies alongside RCTs introduces potential confounding. Heart failure subtypes (HFpEF vs. HFrEF) were not distinguished. Individual patient-level data were not available.
How to read the evidence
This is a PRISMA-compliant meta-analysis primarily of randomized controlled trials (6 RCTs plus 2 observational studies), representing a high level of evidence. The large combined sample size and confirmed robustness are strengths, though moderate heterogeneity and the fact that most trials were not heart failure-specific are limitations.
When this study was published
Published in 2024, this meta-analysis captures data through early 2024. Since then, dedicated heart failure trials (like STEP-HFpEF) have provided direct evidence supporting semaglutide's heart failure benefits.
The bigger picture
This meta-analysis adds heart failure to the growing list of cardiovascular conditions where semaglutide shows benefit — joining atherosclerotic cardiovascular disease (SELECT trial), kidney disease, and peripheral arterial disease. The GLP-1 receptor is expressed in the heart, and preclinical studies have shown direct cardioprotective effects including improved myocardial metabolism and reduced inflammation. Dedicated heart failure trials (like STEP-HFpEF) have since demonstrated benefits of semaglutide in heart failure with preserved ejection fraction, validating this meta-analysis's signal.
Questions still open
- Is semaglutide's heart failure benefit driven by weight loss, direct cardiac effects, or both?
- Does the benefit differ between heart failure with preserved versus reduced ejection fraction?
- Should semaglutide be considered as standard add-on therapy for heart failure patients with obesity or diabetes?
Common questions
Can semaglutide help with heart failure?
Should heart failure patients ask about semaglutide?
Read the original research
Semaglutide and heart failure: Updated meta-analysis.
Current problems in cardiology, 49(9), 102721
Citation
Barbagelata, Leandro; Masson, Walter; Lobo, Martín; Bluro, Ignacio. (2024). Semaglutide and heart failure: Updated meta-analysis.. Current problems in cardiology, 49(9), 102721. https://doi.org/10.1016/j.cpcardiol.2024.102721